US3577522A - Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes - Google Patents

Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes Download PDF

Info

Publication number
US3577522A
US3577522A US865521A US3577522DA US3577522A US 3577522 A US3577522 A US 3577522A US 865521 A US865521 A US 865521A US 3577522D A US3577522D A US 3577522DA US 3577522 A US3577522 A US 3577522A
Authority
US
United States
Prior art keywords
shock
ethylene oxide
blood plasma
treatment
polypropylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US865521A
Inventor
Alan C Hymes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyandotte Chemicals Corp
Original Assignee
Wyandotte Chemicals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyandotte Chemicals Corp filed Critical Wyandotte Chemicals Corp
Application granted granted Critical
Publication of US3577522A publication Critical patent/US3577522A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids

Definitions

  • the present invention relates to a method for the treat ment of shock. More particularly, the invention relates to the use of certain solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes in the treatment of shock.
  • Shock may be defined as the failure to profuse blood through the capillaries of organs. It is often caused by the loss of excessive amounts of blood. It is well known that of utmost immediate concern in the treatment of shock is the control of the circulating blood volume. Since the body has lost blood, it is necessary in the treat ment of shock that either blood or a blood substitute be immediately injected into the body in shock.
  • a material which will perform as a substitute therefor.
  • a material must possess the following properties: (1) it must retain a sufficient molecular size to remain in the blood space, thus creating an osmotic pressure great enough to retain the solvent (water) within the circulation, (2) it must be miscible with blood, (3) it must be nonantigenic, nontoxic and nonpyretogenic, (4) it must not draw water from the cellular area of the body, (5) it must be readily available and stable under prolonged storage conditions, and (6) when no longer needed, it must be readily discharged from the body circulation.
  • the process of the present invention comprises the improvement in the treatment of shock which com-prises employing as a blood or blood plasma substitute, an isotonic (isosrnotic) solution containing from 0.375 to 1.5 millimoles/liter of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of from- 950 to 4000, preferably from 1750 to 4000, and b is an integer such that the hydrophile portion represented by (C H O) constitutes from about 50% to by weight of the compound.
  • isotonic or isosrnotic solution is meant a solution having the same osmotic pressure as blood. This phrase is well known in the art.
  • Illustrative solutions which may be employed in the preparation of the blood plasma substitutes employed in the process of the present invention include saline (a solution of sodium chloride, containing 8.5 to 9.5 grams of salt in 1000 cc. of purified water), Ringers solution, lac tated Ringers solution, Krebs-Ringers solution, and various sugar solutions.
  • saline a solution of sodium chloride, containing 8.5 to 9.5 grams of salt in 1000 cc. of purified water
  • Ringers solution containing 8.5 to 9.5 grams of salt in 1000 cc. of purified water
  • Ringers solution containing 8.5 to 9.5 grams of salt in 1000 cc. of purified water
  • Ringers solution containing 8.5 to 9.5 grams of salt in 1000 cc. of purified water
  • Ringers solution containing 8.5 to 9.5 grams of salt in 1000 cc. of purified water
  • lactated Ringers solution containing 8.5 to 9.5 grams of salt in 1000 cc. of purified water
  • lactated Ringers solution
  • compositions comprising amounts of products outside of the above-cited range have been found to be unacceptable blood plasma substitutes.
  • compositions comprising high concentrations of the above condensation product may be employed in the treatment of shock by injecting small amounts of these compositions into the body circulation. By this procedure, water is drawn from the body into the circulation, thus diluting the compositions.
  • compositions containing the concentrations of ethylene oxide-polypropylene glycol condensation products within the range cited above are employed by parenteral injection, preferably intravenous injection, into a body in shock.
  • the condensation products which are operable in the present invention are prepared by condensing ethylene oxide with polypropylene glycol.
  • the products must contain at least 50% by weight of ethylene oxide.
  • the polypropylene glycol base must have a molecular weight of at least 950. It has been determined that products outside of these limits are not satisfactory blood plasma substitutes for various reasons. For example, a product containing less than 50% ethylene oxide is not sufficiently nontoxic to be useful whereas a product containing a hydrophobic base molecular weight of less than about 950 has completely different physical properties, particularly with regard to solubility, than the products useful in the present invention.
  • Illustrative ethylene oxide-polypropylene glycol condensation products which may be employed in the preparation of the isotonic solutions useful in the present invention include:
  • EXAMPLE I An isotonic solution was prepared by dissolving 0.4% by weight of a 7800 molecular weight polyol prepared by condensing ethylene oxide with a polypropylene glycol having a molecular weight of 1750, said polyol containing approximately 80% ethylene oxide in lactated Ringers solution (0.513 millimole/liter). Ringers lactated is a solution of 570 to 630 mg. sodium chloride, 290 to 330 mg. sodium lactate, 18 to 22 mg. calcium chloride, and 27 to 33 mg. potassium chloride in each 100 cc. of distilled water. The solution was then tested as a blood plasma substitute in the treatment of mongrel dogs in hemorrhagic shock.
  • EXAMPLE II A solution containing 1.0 millimole/liter of a polyol having a molecular weight of about 16,250 and containing approximately 80% ethylene oxide prepared by the reaction of ethylene oxide with a polypropylene glycol having a molecular weight of 3250 was prepared by dissolving 16.25 grams of said polyol in 10 liters of saline solution containing 9 grams of sodium chloride in 1000 cc. of water. The solution is then employed in the manner described in Example I. Results similar to those of Example I are obtained.
  • EXAMPLE III An isotonic solution was prepared by dissolving 0.4% by weight of a 7800 molecular weight polyol prepared by condensing ethylene oxide with a polypropylene glycol having a molecular weight of 1750, said polyol containing approximately 80% ethylene oxide in lactated Ringers solution (0.513 millimole/liter). Ringers lactated is a solution of 570 to 630 mg. sodium chloride, 290 to 330 mg. sodium lactate, 18 to 22 mg. calcium chloride, and 27 to 33 mg. potassium chloride in each 100 cc. of distilled water. The solution was then tested as a blood plasma substitute in the treatment of male beagle dogs, six to eight months of age in hemorrhagic shock.
  • a group of 25 of these dogs was treated by returning all blood withdrawn. Five of these dogs survived (20% survival). A group of 26 of these dogs was treated by returning all blood withdrawn plus two times the amount of blood withdrawn of lactated Ringers solution. Eleven of these dogs survived (42% survival). A group of 24 of these dogs was treated by returning all blood withdrawn plus two times the amount of blood withdrawn of the above-described isotonic solution. Sixteen of these dogs survived (67% survival).
  • a method for the treatment of shock which comprises injecting into a body in shock as a blood plasma substitute an isotonic solution containing from 0.375 to 1.5 millimoles/liter of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of 950 to 4000 and b is an integer such that the hydrophile portion represented by (0 1-1 0) constitues from about 50% to by weight of the compound.
  • the isotonic solution comprises from 0.375 to 1.5 millimoles/liter of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C l-I 0) has a molecular weight of from 1750 to 4000.
  • the isotonic solution comprises from 0.375 to 1.5 millimoles of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of 950 to 4000 and b is an integer such that the hydrophile portion represented by (C H O) constitues from about 50% to 90% by weight of the compound per liter of lactated Ringers solution.
  • the isotonic solution comprises from 0.375 to 1.5 millimoles of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of 950 to 4000 and b is an integer such that the hydrophile portion represented by (C H O) constitues from about 50% to 90% by weight of the compound per liter of saline solution.

Abstract

ISOTONIC SOLUTIONS OF CERTAIN ETHYLENE OXIDE-POLYPROPYLENE GLYCOL CONDENSATION PRODUCTS HAVE BEEN FOUND TO BE EXTREMELY EFFECTIVE AS BLOOD PLASMA SUBSTITUTES IN THE TREATMENT OF SHOCK.

Description

United States Patent 3,577,522 METHODS FOR THE TREATMENT OF SHOCK WITH ETHYLENE OXIDE-POLYPROPYLENE GLYCOL CONDENSATES AS BLOOD PLASMA SUBSTITUTES Alan C. Hymes, Hopkins, Minn., assignor to Wyandotte Chemicals Corporation, Wyandotte, Mich.
No Drawing. Continuation-impart of application Ser. No. 762,633, Sept. 25, 1968, which is a continuation-in-part of application Ser. No. 670,408, Sept. 25, 1967. This application Oct. 10, 1969, Ser. No. 865,521
Int. Cl. A61k 27/00 U.S. Cl. 424-48 Claims ABSTRACT OF THE DISCLOSURE Isotonic solutions of certain ethylene oxide-polypropylene glycol condensation products have been found to be extremely effective as blood plasma substitutes in the treatment of shock.
This application is a continuation-in-part of copending U.S. patent application Ser. No. 762,633 filed Sept. 25, 1968, now abandoned, which is in turn a continuation-inpart of U.S. patent application Ser. No. 670,408 filed Sept. 25, 1967, now abandoned.
The present invention relates to a method for the treat ment of shock. More particularly, the invention relates to the use of certain solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes in the treatment of shock.
Shock may be defined as the failure to profuse blood through the capillaries of organs. It is often caused by the loss of excessive amounts of blood. It is well known that of utmost immediate concern in the treatment of shock is the control of the circulating blood volume. Since the body has lost blood, it is necessary in the treat ment of shock that either blood or a blood substitute be immediately injected into the body in shock.
Because of the high cost and scarcity of blood plasma, the art has long been in need of a material which will perform as a substitute therefor. To be useful as a blood plasma substitute, a material must possess the following properties: (1) it must retain a sufficient molecular size to remain in the blood space, thus creating an osmotic pressure great enough to retain the solvent (water) within the circulation, (2) it must be miscible with blood, (3) it must be nonantigenic, nontoxic and nonpyretogenic, (4) it must not draw water from the cellular area of the body, (5) it must be readily available and stable under prolonged storage conditions, and (6) when no longer needed, it must be readily discharged from the body circulation. With such formidable requirements, it is little wonder that the art has not heretofore found any material which satisfactorily performs as a blood plasma substitute. This is so notwithstanding the fact that various materials such as salt solutions, gelatin derivatives, various proteins and derivatives thereof, mannitol, starch and dextrans have been investigated as blood plasma substitutes. However, these materials all lack one or more of the above requirements, thereby rendering them not totally acceptable as blood plasma substitutes.
Now, in accordance with the present invention, it has been determined that certain solutions of ethylene oxidepolypropylene glycol condensation products may be effectively employed as blood plasma substitutes in the treatment of shock. It has been determined that by the process of the present invention, the circulating blood volume of the body may be quickly and effectively restored Without any subsequent injurious effect on the body system. Thus, the process of the present invention comprises the improvement in the treatment of shock which com-prises employing as a blood or blood plasma substitute, an isotonic (isosrnotic) solution containing from 0.375 to 1.5 millimoles/liter of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of from- 950 to 4000, preferably from 1750 to 4000, and b is an integer such that the hydrophile portion represented by (C H O) constitutes from about 50% to by weight of the compound. By the phrase isotonic or isosrnotic solution is meant a solution having the same osmotic pressure as blood. This phrase is well known in the art. Illustrative solutions which may be employed in the preparation of the blood plasma substitutes employed in the process of the present invention include saline (a solution of sodium chloride, containing 8.5 to 9.5 grams of salt in 1000 cc. of purified water), Ringers solution, lac tated Ringers solution, Krebs-Ringers solution, and various sugar solutions.
As stated above, critical amounts of certain ethylene oxide-polypropylene glycol condensation products mustbe employed in the preparation of the blood plasma substitutes useful in the present invention. Generally, the iso tonic solutions useful in the present invention will comprise from 0.375 to 1.5 millimoles/ liter of the above-mentioned ethylene oxide-polypropylene glycol condensation products. Compositions comprising amounts of products outside of the above-cited range have been found to be unacceptable blood plasma substitutes. Although it is not a preferred manner of carrying out the method of the present invention, compositions comprising high concentrations of the above condensation product may be employed in the treatment of shock by injecting small amounts of these compositions into the body circulation. By this procedure, water is drawn from the body into the circulation, thus diluting the compositions. The net effeet is the employment of compositions containing the concentrations of ethylene oxide-polypropylene glycol condensation products within the range cited above. Thus, the blood plasma substitutes of the present invention are employed by parenteral injection, preferably intravenous injection, into a body in shock.
The condensation products which are operable in the present invention are prepared by condensing ethylene oxide with polypropylene glycol. A more detailed discussion of the preparation of these products is found in U.S. 2,674,619. To be useful in the present invention, the products must contain at least 50% by weight of ethylene oxide. Furthermore, the polypropylene glycol base must have a molecular weight of at least 950. It has been determined that products outside of these limits are not satisfactory blood plasma substitutes for various reasons. For example, a product containing less than 50% ethylene oxide is not sufficiently nontoxic to be useful whereas a product containing a hydrophobic base molecular weight of less than about 950 has completely different physical properties, particularly with regard to solubility, than the products useful in the present invention.
Illustrative ethylene oxide-polypropylene glycol condensation products which may be employed in the preparation of the isotonic solutions useful in the present invention include:
approxiapproxiapproxi- (4) 7500 molecular weight polyol containing approximately 70% by weight ethylene oxide,
(5) 16,250 molecular weight polyol containing approximately 80% by weight ethylene oxide,
(6) 13,330 molecular weight polyol containing approximately 70% by weight ethylene oxide,
(7) 9500 molecular weight polyol containing approximately 90% by weight ethylene oxide The following examples illustrate the nature of the invention. All parts are by weight unless otherwise stated.
EXAMPLE I An isotonic solution was prepared by dissolving 0.4% by weight of a 7800 molecular weight polyol prepared by condensing ethylene oxide with a polypropylene glycol having a molecular weight of 1750, said polyol containing approximately 80% ethylene oxide in lactated Ringers solution (0.513 millimole/liter). Ringers lactated is a solution of 570 to 630 mg. sodium chloride, 290 to 330 mg. sodium lactate, 18 to 22 mg. calcium chloride, and 27 to 33 mg. potassium chloride in each 100 cc. of distilled water. The solution was then tested as a blood plasma substitute in the treatment of mongrel dogs in hemorrhagic shock.
Twelve dogs were subjected to hemorrhagic shock in a standardized manner as described by Wiggens and modified by Moyer et al., Archives of Surgery, volume 93, page 537, October 1966, A Bioassay of Treatment of Hemorrhagic Shock. A group of four of these dogs was treated by returning all blood withdrawn plus two times the amount of blood withdrawn of the above salt solution. All four dogs survived without any complications. A group of eight of these dogs was treated by simply returning all blood withdrawn. Three of these dogs survived without any complications while the other five dogs expired.
EXAMPLE II A solution containing 1.0 millimole/liter of a polyol having a molecular weight of about 16,250 and containing approximately 80% ethylene oxide prepared by the reaction of ethylene oxide with a polypropylene glycol having a molecular weight of 3250 was prepared by dissolving 16.25 grams of said polyol in 10 liters of saline solution containing 9 grams of sodium chloride in 1000 cc. of water. The solution is then employed in the manner described in Example I. Results similar to those of Example I are obtained.
EXAMPLE III An isotonic solution was prepared by dissolving 0.4% by weight of a 7800 molecular weight polyol prepared by condensing ethylene oxide with a polypropylene glycol having a molecular weight of 1750, said polyol containing approximately 80% ethylene oxide in lactated Ringers solution (0.513 millimole/liter). Ringers lactated is a solution of 570 to 630 mg. sodium chloride, 290 to 330 mg. sodium lactate, 18 to 22 mg. calcium chloride, and 27 to 33 mg. potassium chloride in each 100 cc. of distilled water. The solution was then tested as a blood plasma substitute in the treatment of male beagle dogs, six to eight months of age in hemorrhagic shock.
Seventy-five dogs were subjected to hemorrhagic shock in a standardized manner as described by Wiggens and modified by Moyer et al., Archives of Surgery, volume 93, page 537, October 1966, A Bioassay of Treatment of Hemorrhagic Shock. Moyers method was further modified in the following manner: (1) all animals were preinfused with normal saline ml./l ilogram), to 60 minutes prior to onset of hemorrhage; (2) the period of shock was at a mean arterial blood pressure of 75 mm. mercury for 90 minutes. At the end of this two-hour period, the animal was randomized for treatment in the manner described below.
A group of 25 of these dogs was treated by returning all blood withdrawn. Five of these dogs survived (20% survival). A group of 26 of these dogs was treated by returning all blood withdrawn plus two times the amount of blood withdrawn of lactated Ringers solution. Eleven of these dogs survived (42% survival). A group of 24 of these dogs was treated by returning all blood withdrawn plus two times the amount of blood withdrawn of the above-described isotonic solution. Sixteen of these dogs survived (67% survival).
While the above examples specifically illustrate the treatment of dogs in accordance with the process of the present invention, it is to be understood that the invention is applicable to all living animal bodies. Representative of such living animal bodies are domestic animals such as dogs cats; farm animals such as horses, cows, and pigs; and wild animals such as chimpanzees and monkeys.
What is claimed is:
1. A method for the treatment of shock which comprises injecting into a body in shock as a blood plasma substitute an isotonic solution containing from 0.375 to 1.5 millimoles/liter of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of 950 to 4000 and b is an integer such that the hydrophile portion represented by (0 1-1 0) constitues from about 50% to by weight of the compound.
2. The method of claim 1 wherein the isotonic solution comprises from 0.375 to 1.5 millimoles/liter of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C l-I 0) has a molecular weight of from 1750 to 4000.
3. The method of claim 1 wherein the isotonic solution comprises from 0.375 to 1.5 millimoles of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of 950 to 4000 and b is an integer such that the hydrophile portion represented by (C H O) constitues from about 50% to 90% by weight of the compound per liter of lactated Ringers solution.
4. The method of claim 1 wherein the isotonic solution comprises from 0.375 to 1.5 millimoles of a compound of the formula wherein a is an integer such that the hydrophobe base represented by (C H O) has a molecular weight of 950 to 4000 and b is an integer such that the hydrophile portion represented by (C H O) constitues from about 50% to 90% by weight of the compound per liter of saline solution.
5. The method of claim 1 wherein the isotonic solution is intravenously injected into a body in shock.
References Cited UNITED STATES PATENTS 2,819,199 l/1958 Kalish 424342 3,122,478 2/1964 Lafon 424--342 3,150,043 9/1964 Lafon 42478 3,202,578 8/1965 Parker 424l06 3,228,834 1/1966 Gans et a1. 42478 STANLEY I. FRIEDMAN, Primary Examiner US. Cl. X.R. 424-4342
US865521A 1969-10-10 1969-10-10 Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes Expired - Lifetime US3577522A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86552169A 1969-10-10 1969-10-10

Publications (1)

Publication Number Publication Date
US3577522A true US3577522A (en) 1971-05-04

Family

ID=25345691

Family Applications (1)

Application Number Title Priority Date Filing Date
US865521A Expired - Lifetime US3577522A (en) 1969-10-10 1969-10-10 Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes

Country Status (1)

Country Link
US (1) US3577522A (en)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3893990A (en) * 1973-04-05 1975-07-08 Baxter Laboratories Inc Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene
US3931111A (en) * 1972-02-29 1976-01-06 Ceskoslovenska Akadamie Ved Soluble hydrophilic polymers and process for processing the same
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US4185618A (en) * 1976-01-05 1980-01-29 Population Research, Inc. Promotion of fibrous tissue growth in fallopian tubes for female sterilization
EP0103290A2 (en) * 1982-09-14 1984-03-21 Intermedicat Gmbh Pharmaceutical compositions for treating undesirable coalescence and their use
US4506018A (en) * 1982-12-30 1985-03-19 Becton, Dickinson And Company Blood diluent
US4837014A (en) * 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US4873083A (en) * 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4997644A (en) * 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5032394A (en) * 1986-05-15 1991-07-16 Emory University Method of treating burns
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US5064643A (en) * 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5078995A (en) * 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US5089260A (en) * 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US5152979A (en) * 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5240701A (en) * 1986-05-15 1993-08-31 Emory University Method of performing angioplasty procedures
US5250294A (en) * 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5523492A (en) * 1991-03-19 1996-06-04 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5605687A (en) * 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
US5622649A (en) * 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5658560A (en) * 1994-01-18 1997-08-19 Serikov; Vladimir B. Method of treating endotoxemia by administering tyloxapol
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5811088A (en) * 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
USRE38558E1 (en) 1991-03-19 2004-07-20 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US20040248833A1 (en) * 1991-03-19 2004-12-09 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US7135554B1 (en) * 2004-01-27 2006-11-14 Biopure Corporation Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931111A (en) * 1972-02-29 1976-01-06 Ceskoslovenska Akadamie Ved Soluble hydrophilic polymers and process for processing the same
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US3893990A (en) * 1973-04-05 1975-07-08 Baxter Laboratories Inc Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene
US4185618A (en) * 1976-01-05 1980-01-29 Population Research, Inc. Promotion of fibrous tissue growth in fallopian tubes for female sterilization
EP0103290A2 (en) * 1982-09-14 1984-03-21 Intermedicat Gmbh Pharmaceutical compositions for treating undesirable coalescence and their use
EP0103290A3 (en) * 1982-09-14 1984-09-05 Intermedicat Gmbh Pharmaceutical compositions for treating undesirable coalescence and their use
US4506018A (en) * 1982-12-30 1985-03-19 Becton, Dickinson And Company Blood diluent
US5152979A (en) * 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4873083A (en) * 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US4997644A (en) * 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5032394A (en) * 1986-05-15 1991-07-16 Emory University Method of treating burns
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5064643A (en) * 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5078995A (en) * 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US5089260A (en) * 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US4837014A (en) * 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5240701A (en) * 1986-05-15 1993-08-31 Emory University Method of performing angioplasty procedures
US5250294A (en) * 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US5811088A (en) * 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
EP0409940A1 (en) * 1988-12-29 1991-01-30 Univ Emory Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids.
EP0409940B1 (en) * 1988-12-29 1997-03-12 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5990241A (en) * 1991-03-19 1999-11-23 Cytrx, Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
USRE37285E1 (en) 1991-03-19 2001-07-17 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolmers with improved biological activity
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US20040248833A1 (en) * 1991-03-19 2004-12-09 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
US5691387A (en) * 1991-03-19 1997-11-25 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolmers with improved biological activity
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5523492A (en) * 1991-03-19 1996-06-04 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
USRE38558E1 (en) 1991-03-19 2004-07-20 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
USRE36665E (en) * 1991-03-19 2000-04-18 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US6747064B2 (en) 1991-03-19 2004-06-08 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US6359014B1 (en) 1991-03-19 2002-03-19 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5622649A (en) * 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5605687A (en) * 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
US5658560A (en) * 1994-01-18 1997-08-19 Serikov; Vladimir B. Method of treating endotoxemia by administering tyloxapol
US7135554B1 (en) * 2004-01-27 2006-11-14 Biopure Corporation Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
US20070219335A1 (en) * 2004-01-27 2007-09-20 Page Thomas C Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
US7459535B2 (en) 2004-01-27 2008-12-02 Biopure Corporation Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
US20090137762A1 (en) * 2004-01-27 2009-05-28 Biopure Corporation Method of forming a polymerized hemoglobin solution from stabilized hemoglobin

Similar Documents

Publication Publication Date Title
US3577522A (en) Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes
US3590125A (en) Physiological salt solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes
DE69433478T2 (en) USE OF STAINOXIDE ADDUCTS TO PREVENT THROMBOSES ON ARTIFICIAL AND VASCULAR SURFACES
Olafsson et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon.
JP4245192B2 (en) A composition comprising PVP having an average molecular weight of 3,000 to 14,000 daltons
ES2264274T5 (en) Antimicrobial compositions comprising taurolidine, citric acid and sodium citrate
Thomas et al. The effect of cortisone on the Shwartzman reaction: The production of lesions resembling the dermal and generalized Shwartzman reactions by a single injection of bacterial toxin in cortisone-treated rabbits
EP0359574B1 (en) Aqueous antimicrobial solutions for contact lens care
US3641240A (en) Method for the treatment of an embolus or thrombus
EP1478339B9 (en) Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
Lee et al. Ultrapure, stroma-free, polymerized bovine hemoglobin solution: evaluation of renal toxicity
KR101305649B1 (en) Product containing prostaglandin having fluorine atom in molecule
DE3150318C2 (en) "Process for the preparation of a polysaccharide derivative of fibrinolysin"
EP1226829B1 (en) Stabilised liquid preparations of the protease or its proenzyme which activitate the blood coagulation factor VII
US3864478A (en) Storage-stable hemoglobin solutions and method for their preparation
JPS6214271B2 (en)
EP1294385A1 (en) Method for the production of artificial oxygen carriers from covalently cross linking haemoglobin with improved functional properties of haemoglobin by cross-linking in the presence of chemically non-reacting effectors of the oxygen affinity of the haemoglobin
FI75991C (en) Process for the preparation of stable isotonic liquid composition, which can also be used as an ophthalmic medicine
SK2594A3 (en) Pharmaceutical preparation for peritoneal dialysis
JPS59157017A (en) Gamma-globulin preparation for intravenous injection
US5985260A (en) Disinfection of blood and biologicals with active albumin-iodine complex
FR2629346A1 (en) SYNERGISTICALLY ACTIVE VETERINARY COMPOSITIONS AND METHOD OF MANUFACTURING SAME
König ‘Pink eye’or ‘zere oogjes’ or Keratoconjunctivitis Infectiosa Ovis (KIO) Clinical efficacy of a number of antimicrobial therapies
Yarom et al. T-2 toxin effect on the ultrastructure of myocardial microvasculature.
CH638401A5 (en) Process for the preparation of haemoglobin preparations having an increased oxygen delivery